Pharmamarketeer

EMA’s COMP issues positive opinion on orphan drug status for Santhera’s POL6014 to treat cystic fibrosis

Santhera Pharmaceuticals has announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has issued a positive opinion on orphan drug designation for POL6014

Reageer

Medhc-fases-banner
Advertentie(s)